AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11429357 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study 9678820 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebeverine (135 mg t.d.s.)
Number of subjects: 9
Study 9678820 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 9
Study 8036831 — intervention group
Group type: COMPARATOR
Intervention: EcSf2a-2 vaccine (doses ranging from 2.3 to 9.0 x 10(8) CFU, given on days 0, 3, 14, and 17)
Number of subjects: 244
Study 8036831 — intervention group
Group type: COMPARATOR
Intervention: EcSf2a-2 vaccine
Number of subjects: 244
Study 2498397 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexetidine/zinc citrate toothpaste
Number of subjects: 0
Study 2498397 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% Triclosan toothpaste
Number of subjects: 0
Study 2498397 — intervention group
Group type: EXPERIMENTAL
Intervention: Amyloglucosidase/glucose oxidase toothpaste
Number of subjects: 0
Study 2498397 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride/sodium monofluorophosphate toothpaste
Number of subjects: 0
Study 2498397 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoride toothpaste
Number of subjects: 0
Study 6407504 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (mean dose 101 mg/day)
Number of subjects: 69
Study 6407504 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (mean dose 127 mg/day)
Number of subjects: 69
Study 6407504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 31771387 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait with sub-motor threshold NMES
Number of subjects: 22
Study 31771387 — intervention group
Group type: COMPARATOR
Intervention: Gait with sham NMES
Number of subjects: 22
Study 30884111 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Bone Regeneration (GBR)
Number of subjects: 42
Study 30884111 — intervention group
Group type: COMPARATOR
Intervention: Autogenous Block Graft (ABG)
Number of subjects: 42
Study 30884111 — intervention group
Group type: COMPARATOR
Intervention: ABG
Number of subjects: 42
Study 30884111 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 28766650 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of non-photoactive tertiary polymer phase (PMMA) in the binary BHJ blend
Number of subjects: 0
Study 28766650 — intervention group
Group type: COMPARATOR
Intervention: Binary BHJ blend (P3HT:fullerene) without PMMA
Number of subjects: 0
Study 25655884 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 95
Study 25655884 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behaviors
Number of subjects: 95
Study 25655884 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity activities
Number of subjects: 95
Study 25655884 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity lifestyle activities
Number of subjects: 95
Study 25655884 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate- to vigorous-intensity ambulatory activities
Number of subjects: 95
Study 24839916 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/day ferrous fumarate plus 1mg/day folic acid (FFFA group)
Number of subjects: 112
Study 24839916 — intervention group
Group type: COMPARATOR
Intervention: 600 mg/day ferrous fumarate alone (FF group)
Number of subjects: 112
Study 24839916 — intervention group
Group type: COMPARATOR
Intervention: 600 mg/day ferrous fumarate (both groups)
Number of subjects: 112
Study 21857244 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketamine (group B)
Number of subjects: 150
Study 21857244 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group A)
Number of subjects: 150
Study 21857244 — intervention group
Group type: COMPARATOR
Intervention: Oral fentanyl (group C)
Number of subjects: 150
Study 21118495 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe + atorvastatin 40 mg
Number of subjects: 579
Study 21118495 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin 80 mg
Number of subjects: 579
Study 17658249 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled formoterol fumarate 12 microg twice daily for 14 days
Number of subjects: 21
Study 17658249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 16363240 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg daily
Number of subjects: 87
Study 16363240 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg twice daily
Number of subjects: 87
Study 16363240 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal pregnancies)
Number of subjects: 87
Study 16363240 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (both dosages)
Number of subjects: 87
Study 12523169 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO (4000 units, 3 times a week for 4 months)
Number of subjects: 65
Study 12523169 — intervention group
Group type: COMPARATOR
Intervention: Control group (haematocrit values above 28%, not treated with rhEPO)
Number of subjects: 65
Study 9456244 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative fluorescence image analysis (QFIA) of DNA ploidy and nuclear morphology
Number of subjects: 1331
Study 9456244 — intervention group
Group type: COMPARATOR
Intervention: Traditional cytology
Number of subjects: 1331
Study 9456244 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of QFIA and traditional cytology
Number of subjects: 1331
Study 9456244 — intervention group
Group type: EXPERIMENTAL
Intervention: QFIA variables
Number of subjects: 1331
Study 9456244 — intervention group
Group type: COMPARATOR
Intervention: Cytological diagnoses
Number of subjects: 1331
Study 8077815 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 24
Study 8077815 — intervention group
Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 24
Study 2806891 — intervention group
Group type: EXPERIMENTAL
Intervention: Navane (thiothixene)
Number of subjects: 17
Study 2806891 — intervention group
Group type: COMPARATOR
Intervention: Haldol
Number of subjects: 17
Study 72240 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc therapy
Number of subjects: 8
Study 72240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30959472 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cryotherapy (ice chips) during oxaliplatin infusion
Number of subjects: 62
Study 30959472 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care treatment (control)
Number of subjects: 62
Study 28650086 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-directed thrombolysis (CDT)
Number of subjects: 0
Study 28650086 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation alone
Number of subjects: 0
Study 28650086 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator (IV tPA)
Number of subjects: 0
Study 28650086 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic thrombolysis
Number of subjects: 0
Study 25646792 — intervention group
Group type: EXPERIMENTAL
Intervention: Infacort (oral hydrocortisone granules with taste masking)
Number of subjects: 0
Study 23581723 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's beliefs about the objectivity of social categories
Number of subjects: 109
Study 23581723 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's beliefs about race and ethnicity
Number of subjects: 109
Study 21807324 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 44
Study 21807324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 19500848 — intervention group
Group type: EXPERIMENTAL
Intervention: hh‐DCT
Number of subjects: 50
Study 19500848 — intervention group
Group type: COMPARATOR
Intervention: sl‐DCT
Number of subjects: 50
Study 19500848 — intervention group
Group type: EXPERIMENTAL
Intervention: hh‐DCT and sl‐DCT
Number of subjects: 50
Study 17511176 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone and Cefuroxime Sodium
Number of subjects: 43
Study 17511176 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime Sodium
Number of subjects: 43
Study 15505499 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal GTN (0.6 mg/h/24 hrs for 6 days)
Number of subjects: 16
Study 15505499 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 16
Study 11148592 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood-based educational activities, dissemination of health education materials, media campaign, continuing medical education seminars for physicians
Number of subjects: 788
Study 11148592 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater exposure to intervention elements
Number of subjects: 788
Study 11148592 — intervention group
Group type: COMPARATOR
Intervention: Control group (women in Los Angeles and Orange Counties)
Number of subjects: 788
Study 9672169 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha 3 MU tiw for 6 months
Number of subjects: 336
Study 9672169 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha 6 MU tiw for 8 weeks followed by down-titration (3,1 MU tiw)
Number of subjects: 336
Study 9672169 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha 6 MU tiw
Number of subjects: 336
Study 9672169 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha 3 MU tiw
Number of subjects: 336
Study 9672169 — intervention group
Group type: EXPERIMENTAL
Intervention: Week 4 HCV RNA not detectable
Number of subjects: 336
Study 8062564 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (mean loading dose 0.24 mg/kg; mean maintenance dose 0.76 mg/kg/hr)
Number of subjects: 84
Study 8062564 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (mean loading dose 0.012 mg/kg; mean maintenance dose 0.018 mg/kg/hr)
Number of subjects: 84
Study 3248129 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate buffered fluid
Number of subjects: 8
Study 3248129 — intervention group
Group type: COMPARATOR
Intervention: Bicarbonate buffered fluid
Number of subjects: 8
Study 31244297 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-Centered Empowerment Model (FCEM) implemented in four stages during four sessions of 20-40 minutes
Number of subjects: 78
Study 31244297 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 78
Study 28376642 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck irradiation
Number of subjects: 15
Study 28376642 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 15
Study 26172928 — intervention group
Group type: EXPERIMENTAL
Intervention: FRAX® tool assessment for clinical risk factors of OP
Number of subjects: 0
Study 24292619 — intervention group
Group type: EXPERIMENTAL
Intervention: HEPHAISTOS orthosis
Number of subjects: 11
Study 21562061 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (Rsg)
Number of subjects: 74
Study 19430757 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative pain
Number of subjects: 165
Study 19430757 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute preoperative pain
Number of subjects: 165
Study 19430757 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic preoperative pain
Number of subjects: 165
Study 19430757 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 165
Study 19430757 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-being
Number of subjects: 165
Study 16836761 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive Care Checklist Forms used in intervention clinics
Number of subjects: 1117
Study 16836761 — intervention group
Group type: COMPARATOR
Intervention: Control group (no checklist form)
Number of subjects: 1117
Study 12734789 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise for 60 min at 50% of VO(2) max
Number of subjects: 6
Study 12734789 — intervention group
Group type: COMPARATOR
Intervention: Resting session (no exercise)
Number of subjects: 6
Study 10814693 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention
Number of subjects: 55
Study 10814693 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 55
Study 9186825 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-ribavirin combination therapy (dosage as for monotherapy) for 6 months
Number of subjects: 186
Study 9186825 — intervention group
Group type: COMPARATOR
Intervention: Interferon monotherapy (3 MU 3x/week) for 6 months
Number of subjects: 186
Study 9186825 — intervention group
Group type: COMPARATOR
Intervention: Ribavirin monotherapy (1000-1200 mg/day) for 6 months
Number of subjects: 186
Study 9186825 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 patients)
Number of subjects: 186
Study 8355975 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG treatment
Number of subjects: 170
Study 8355975 — intervention group
Group type: COMPARATOR
Intervention: Control (transurethral resection)
Number of subjects: 170
Study 3526803 — intervention group
Group type: EXPERIMENTAL
Intervention: Bardex Urinary Drainage System
Number of subjects: 40
Study 3526803 — intervention group
Group type: COMPARATOR
Intervention: Routine system (silicone‐coated 16F Latex Foley catheter)
Number of subjects: 40
Study 27489004 — intervention group
Group type: EXPERIMENTAL
Intervention: Household Food Insecurity (HFI)
Number of subjects: 121
Study 27489004 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms (measured by PHQ-8)
Number of subjects: 121
Study 27489004 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety symptoms (measured by PROMIS-short)
Number of subjects: 121
Study 27489004 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes distress (measured by PAID-5)
Number of subjects: 121
Study 24990032 — intervention group
Group type: EXPERIMENTAL
Intervention: ALS subjects
Number of subjects: 20
Study 24990032 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 20
Study 24990032 — intervention group
Group type: EXPERIMENTAL
Intervention: Remaining ALS subjects after excluding four with very weak maximum force
Number of subjects: 20
Study 22705016 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm
Number of subjects: 400
Study 22705016 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 400
Study 20521308 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored cognitive-behavioral therapy (CBT) and exercise training (16 sessions over 10 weeks)
Number of subjects: 0
Study 20521308 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control (WLC)
Number of subjects: 0
Study 18668592 — intervention group
Group type: EXPERIMENTAL
Intervention: Abetimus (100 mg/week for up to 22 months)
Number of subjects: 298
Study 18668592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study 15806043 — intervention group
Group type: EXPERIMENTAL
Intervention: DPOAE-grams in tinnitus ears
Number of subjects: 32
Study 15806043 — intervention group
Group type: COMPARATOR
Intervention: Healthy nontinnitus ears
Number of subjects: 32
Study 12897643 — intervention group
Group type: EXPERIMENTAL
Intervention: Safinamide 2 mg/kg oral load
Number of subjects: 0
Study 12897643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9887110 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate (CrPic) supplementation (17.8 micromol Cr/day, 924 microg Cr/day)
Number of subjects: 18
Study 9887110 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 18
Study 8890308 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor unit activity during elbow flexion and extension with varying deceleration magnitudes
Number of subjects: 47
Study 8890308 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor unit activity during elbow flexion and extension with constant acceleration magnitude
Number of subjects: 47
Study 8890308 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor unit activity during extension movements
Number of subjects: 47
Study 8890308 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor unit activity during flexion movements
Number of subjects: 47
Study 8890308 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor unit activity during agonist and antagonist functions
Number of subjects: 47
Study 1706506 — intervention group
Group type: EXPERIMENTAL
Intervention: VVIR pacing
Number of subjects: 21
Study 1706506 — intervention group
Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 21
Study 6513433 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (40 mg doses p.o./day continuously)
Number of subjects: 22
Study 6513433 — intervention group
Group type: COMPARATOR
Intervention: Control group (61 patients treated without additional verapamil therapy)
Number of subjects: 22
Study 30810500 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein (≥30 g of high-quality protein/meal)
Number of subjects: 39
Study 30810500 — intervention group
Group type: COMPARATOR
Intervention: Control (traditional weight loss regimen)
Number of subjects: 39
Study 29956495 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation with small changes (200 kcal/day deficit)
Number of subjects: 599
Study 29956495 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation with large changes (5-10 lb weight loss)
Number of subjects: 599
Study 29956495 — intervention group
Group type: COMPARATOR
Intervention: Self-guided control
Number of subjects: 599
Study 27426466 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction drain used during operation (drain group)
Number of subjects: 86
Study 27426466 — intervention group
Group type: COMPARATOR
Intervention: No suction drain applied (no drain group)
Number of subjects: 86
Study 25415455 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention package (life-skills and health education, vocational training, micro-grants, social supports)
Number of subjects: 315
Study 25415455 — intervention group
Group type: COMPARATOR
Intervention: Life-skills and health education alone
Number of subjects: 315
Study 22494013 — intervention group
Group type: EXPERIMENTAL
Intervention: High stimulation (HS) spinal cord stimulation therapy, controlled with a programmer for a minimum of two hours four times daily.
Number of subjects: 68
Study 22494013 — intervention group
Group type: COMPARATOR
Intervention: Low stimulation (LS) spinal cord stimulation therapy, received above the paresthesia threshold for one min once daily.
Number of subjects: 68
Study 22494013 — intervention group
Group type: COMPARATOR
Intervention: Comparison between HS and LS groups.
Number of subjects: 68
Study 20028832 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Reduction Treatment (SRT)
Number of subjects: 304
Study 20028832 — intervention group
Group type: COMPARATOR
Intervention: Usual Cardiac Care
Number of subjects: 304
Study 17916545 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg/day
Number of subjects: 1045
Study 17916545 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg twice daily plus lansoprazole 30 mg once daily
Number of subjects: 1045
Study 16254090 — intervention group
Group type: EXPERIMENTAL
Intervention: Target believed to be dead
Number of subjects: 0
Study 16254090 — intervention group
Group type: COMPARATOR
Intervention: Target believed to be alive
Number of subjects: 0
Study 12709721 — intervention group
Group type: EXPERIMENTAL
Intervention: CGRP (3, 10, and 30 ng x min(‐1) x dL(‐1) forearm)
Number of subjects: 40
Study 12709721 — intervention group
Group type: EXPERIMENTAL
Intervention: CGRP with L‐NMMA (a nitric oxide‐synthase inhibitor)
Number of subjects: 40
Study 12709721 — intervention group
Group type: EXPERIMENTAL
Intervention: CGRP with indomethacin (a cyclooxygenase inhibitor)
Number of subjects: 40
Study 12709721 — intervention group
Group type: EXPERIMENTAL
Intervention: CGRP with tetraethylammonium chloride (TEAC) (a K(+)(Ca)‐channel blocker)
Number of subjects: 40
Study 12709721 — intervention group
Group type: EXPERIMENTAL
Intervention: CGRP with glyburide (INN, glibenclamide) (a K(+)(ATP)‐channel blocker)
Number of subjects: 40
Study 12709721 — intervention group
Group type: COMPARATOR
Intervention: CGRP with placebo (sodium chloride, 0.9%)
Number of subjects: 40
Study 10604047 — intervention group
Group type: EXPERIMENTAL
Intervention: SAM patch (50 micrograms/day estradiol)
Number of subjects: 399
Study 10604047 — intervention group
Group type: COMPARATOR
Intervention: LR patch (50 micrograms/day estradiol)
Number of subjects: 399
Study 10604047 — intervention group
Group type: EXPERIMENTAL
Intervention: SAM patch
Number of subjects: 399
Study 10604047 — intervention group
Group type: COMPARATOR
Intervention: LR patch
Number of subjects: 399
Study 7729633 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg three times a day) + Amoxicillin (750 mg three times a day)
Number of subjects: 270
Study 7729633 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (40 mg three times a day) + Placebo (750 mg three times a day)
Number of subjects: 270
Study 7729633 — intervention group
Group type: COMPARATOR
Intervention: H. pylori‐negative patients
Number of subjects: 270
Study 7729633 — intervention group
Group type: COMPARATOR
Intervention: H. pylori‐positive patients
Number of subjects: 270
Study 2202163 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% cyclosporin in a jelly base
Number of subjects: 2
Study 2202163 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% cyclosporin in an ointment base under occlusion
Number of subjects: 2
Study 2202163 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 2
Study 7408414 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 0.8 mg intravenously
Number of subjects: 12
Study 7408414 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 12
Study 7408414 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 15 mg intravenously
Number of subjects: 12
Study 31694616 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare workers training and peer engagement
Number of subjects: 1800
Study 31694616 — intervention group
Group type: COMPARATOR
Intervention: Control region (Tanga)
Number of subjects: 1800
Study 26787629 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 50 000 IU weekly for 8 weeks, then 50 000 IU monthly for 2 months (group A)
Number of subjects: 71
Study 26787629 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 7000 IU daily for 8 weeks, then 12 500 IU weekly for 2 months (group B)
Number of subjects: 71